News
-
-
-
COMMUNIQUÉ DE PRESSE
BioVersys Reports Corporate Highlights and Financial Results for the Full Year 2025
BioVersys AG reports corporate highlights and financial results for the full year 2025, including significant progress in clinical and regulatory advancements of antibacterial products for MDR bacteria -
-
-
COMMUNIQUÉ DE PRESSE
BioVersys Receives Green Light from US FDA for BV100 HABP/VABP Phase 3 Pivotal Trial Start
BioVersys receives US FDA green light for BV100 HABP/VABP Phase 3 pivotal trial start to address CRABC infections in hospital-acquired bacterial pneumonia. A significant step in developing novel antibacterial products for MDR bacteria -
-
-
COMMUNIQUÉ DE PRESSE
BioVersys Announces First Patient Dosed in Phase 2b Clinical Trial of AlpE in Pulmonary Tuberculosis
BioVersys announces the first patient dosed in a Phase 2b clinical trial of AlpE for pulmonary tuberculosis, collaborating with GSK under UNITE4TB project. Results expected by end of 2027 -
